Modelling myocardial ischemia/reperfusion injury with inflammatory response in human ventricular cardiac organoids
Cell Proliferation · 2025
DOI: 10.1111/cpr.13762 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Proliferation, 2025. Verfasst von Laihai Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Heart Failure Research Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Organoids, Myocardial Reperfusion Injury, Inflammation, Heart Ventricles. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Peak Disciplines (Type IV) of Institutions of Higher Learning in Shanghai.
Abstract (Originalsprache)
Current therapeutic drug exploring targeting at myocardial ischemia/reperfusion (I/R) injury is limited due to the lack of humanized cardiac models that resemble myocardial damage and inflammatory response. Herein, we develop ventricular cardiac organoids from human induced pluripotent stem cells (hiPSCs) and simulate I/R injury by hypoxia/reoxygenation (H/R), which results in increased cardiomyocytes apoptosis, elevated oxidative stress, disrupted morphological structure and decreased beat amplitude. RNA‐seq reveals a potential role of type I interferon (IFN‐I) in this I/R injury model. We then introduce THP‐1 cells and reveal inflammatory responses between monocytes/macrophages and H/R‐induced ventricular cardiac organoids. Furthermore, we demonstrate Anifrolumab, an FDA approved antagonist of IFN‐I receptor, effectively decreases IFN‐I secretion and related gene expression, attenuates H/R‐induced inflammation and oxidative stress in the co‐culture system. This study advances the modelling of myocardial I/R injury with inflammatory response in human cardiac organoids, which provides a reliable platform for preclinical study and drug screening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shanghai Heart Failure Research Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Cardiovascular Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
- Institute for Regenerative Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
- National Stem Cell Translational Resource Center, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China.
- Laboratory of Molecular Cardiology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences (CAS), Shanghai, China.
- Shanghai Institute of Stem Cell Research and Clinical Translation, Shanghai, China.
ORCID-Profile: Huangtian Yang, Yang Liu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Peak Disciplines (Type IV) of Institutions of Higher Learning in Shanghai
Zitieren
APA
Zhang, L., Jiang, Y., Jia, W., Le, W., Liu, J., Zhang, P., Yang, H., Liu, Z., & Liu, Y. (2025). Modelling myocardial ischemia/reperfusion injury with inflammatory response in human ventricular cardiac organoids. Cell Proliferation. https://doi.org/10.1111/cpr.13762
Vancouver
Zhang L, Jiang Y, Jia W, Le W, Liu J, Zhang P, et al. Modelling myocardial ischemia/reperfusion injury with inflammatory response in human ventricular cardiac organoids. Cell Proliferation. 2025. doi:10.1111/cpr.13762
BibTeX
@article{Zhang2025,
author = {Zhang, Laihai and Jiang, Yun and Jia, Wenwen and Le, Wenjun and Liu, Jie and Zhang, Peng and Yang, Huangtian and Liu, Zhongmin and Liu, Yang},
title = {Modelling myocardial ischemia/reperfusion injury with inflammatory response in human ventricular cardiac organoids},
journal = {Cell Proliferation},
year = {2025},
doi = {10.1111/cpr.13762}
}
EUVIMED